N-[2-[4-(Aminosulfonyl)-phenyl]-ethyl]-5-methyl-2-pyrazinecarboxamide
CAS: 33288-71-0
Ref. 3D-FA150607
1g | 991,00 € | ||
50mg | 136,00 € | ||
100mg | 190,00 € | ||
250mg | 396,00 € | ||
500mg | 687,00 € |
Produktinformation
- 2-pyrazinecarboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-5-methyl-
- 4-[2-(5-Methyl-2-pyrazine carboxamido)ethyl]benzene sulfonamide
- 4-[2-(5-Methylpyrazine-2-carboxamido)ethyl]benzenesulfonamide
- 4-[2-(5-Methylpyrazinyl-2-carboxamido)ethyl]benzenesulfonamide
- 5-Methyl-N-[2-(4-sulfamoylphenyl)ethyl]pyrazine-2-carboxamide
- N-[2-[4-(Aminosulfonyl)phenyl]ethyl]-5-methyl-2-pyrazinecarboxamide
- Pyrazinecarboxamide, 5-methyl-N-(p-sulfamoylphenethyl)-
- Pyrazinecarboxamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-5-methyl-
Fluoxetine is a potent inhibitor of the enzyme cytochrome P450 (CYP) 2C19. The inhibition of CYP2C19 by fluoxetine may lead to an increase in the plasma concentration of other drugs that are metabolized by this enzyme, such as glipizide and hydroxycyclohexyl. Fluoxetine inhibits human uric acid secretion and increases plasma concentrations of uric acid. This drug also inhibits human erythrocyte dihydropyrimidine dehydrogenase, leading to increased blood levels of pyrimidines, especially cytotoxic ones like 6-fluoro-3-indoxyl-beta-D-galactopyranoside. Fluoxetine has been shown to have a protective effect against acetaminophen toxicity in rats because it enhances the conversion of acetaminophen to its less toxic metabolite N-acetylcysteine.
Chemische Eigenschaften
Technische Anfrage zu: 3D-FA150607 N-[2-[4-(Aminosulfonyl)-phenyl]-ethyl]-5-methyl-2-pyrazinecarboxamide
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.